358 related articles for article (PubMed ID: 11292011)
1. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers.
Riba J; Rodríguez-Fornells A; Urbano G; Morte A; Antonijoan R; Montero M; Callaway JC; Barbanoj MJ
Psychopharmacology (Berl); 2001 Feb; 154(1):85-95. PubMed ID: 11292011
[TBL] [Abstract][Full Text] [Related]
2. Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers.
Riba J; Anderer P; Morte A; Urbano G; Jané F; Saletu B; Barbanoj MJ
Br J Clin Pharmacol; 2002 Jun; 53(6):613-28. PubMed ID: 12047486
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of ayahuasca administered in two repeated doses.
Dos Santos RG; Grasa E; Valle M; Ballester MR; Bouso JC; Nomdedéu JF; Homs R; Barbanoj MJ; Riba J
Psychopharmacology (Berl); 2012 Feb; 219(4):1039-53. PubMed ID: 21842159
[TBL] [Abstract][Full Text] [Related]
4. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine.
Dos Santos RG; Valle M; Bouso JC; Nomdedéu JF; Rodríguez-Espinosa J; McIlhenny EH; Barker SA; Barbanoj MJ; Riba J
J Clin Psychopharmacol; 2011 Dec; 31(6):717-26. PubMed ID: 22005052
[TBL] [Abstract][Full Text] [Related]
5. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics.
Riba J; Valle M; Urbano G; Yritia M; Morte A; Barbanoj MJ
J Pharmacol Exp Ther; 2003 Jul; 306(1):73-83. PubMed ID: 12660312
[TBL] [Abstract][Full Text] [Related]
6. Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography.
Riba J; Anderer P; Jané F; Saletu B; Barbanoj MJ
Neuropsychobiology; 2004; 50(1):89-101. PubMed ID: 15179026
[TBL] [Abstract][Full Text] [Related]
7. Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers.
Barbanoj MJ; Riba J; Clos S; Giménez S; Grasa E; Romero S
Psychopharmacology (Berl); 2008 Feb; 196(2):315-26. PubMed ID: 18030450
[TBL] [Abstract][Full Text] [Related]
8. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.
Hamill J; Hallak J; Dursun SM; Baker G
Curr Neuropharmacol; 2019; 17(2):108-128. PubMed ID: 29366418
[TBL] [Abstract][Full Text] [Related]
9. Psychedelic Therapy: A Primer for Primary Care Clinicians-N,N-Dimethyltryptamine and Ayahuasca.
Shinozuka K; Tabaac BJ; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
Am J Ther; 2024 Mar-Apr 01; 31(2):e112-e120. PubMed ID: 38518268
[TBL] [Abstract][Full Text] [Related]
10. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant.
Riba J; Romero S; Grasa E; Mena E; Carrió I; Barbanoj MJ
Psychopharmacology (Berl); 2006 May; 186(1):93-8. PubMed ID: 16575552
[TBL] [Abstract][Full Text] [Related]
11. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT).
Cameron LP; Olson DE
ACS Chem Neurosci; 2018 Oct; 9(10):2344-2357. PubMed ID: 30036036
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans.
Valle M; Maqueda AE; Rabella M; Rodríguez-Pujadas A; Antonijoan RM; Romero S; Alonso JF; Mañanas MÀ; Barker S; Friedlander P; Feilding A; Riba J
Eur Neuropsychopharmacol; 2016 Jul; 26(7):1161-75. PubMed ID: 27039035
[TBL] [Abstract][Full Text] [Related]
13. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.
Strassman RJ; Qualls CR; Uhlenhuth EH; Kellner R
Arch Gen Psychiatry; 1994 Feb; 51(2):98-108. PubMed ID: 8297217
[TBL] [Abstract][Full Text] [Related]
14. Dimethyltryptamine: Endogenous Role and Therapeutic Potential.
Rodrigues AV; Almeida FJ; Vieira-Coelho MA
J Psychoactive Drugs; 2019; 51(4):299-310. PubMed ID: 31018803
[TBL] [Abstract][Full Text] [Related]
15. Modulatory effects of ayahuasca on personality structure in a traditional framework.
Netzband N; Ruffell S; Linton S; Tsang WF; Wolff T
Psychopharmacology (Berl); 2020 Oct; 237(10):3161-3171. PubMed ID: 32700023
[TBL] [Abstract][Full Text] [Related]
16. Health status of ayahuasca users.
Barbosa PC; Mizumoto S; Bogenschutz MP; Strassman RJ
Drug Test Anal; 2012; 4(7-8):601-9. PubMed ID: 22761152
[TBL] [Abstract][Full Text] [Related]
17. Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively.
Riba J; Rodríguez-Fornells A; Barbanoj MJ
Psychopharmacology (Berl); 2002 Dec; 165(1):18-28. PubMed ID: 12474114
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA
Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127
[TBL] [Abstract][Full Text] [Related]
19. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca.
McKenna DJ; Towers GH; Abbott F
J Ethnopharmacol; 1984 Apr; 10(2):195-223. PubMed ID: 6587171
[TBL] [Abstract][Full Text] [Related]
20. Altered State of Consciousness and Mental Imagery as a Function of N, N-dimethyltryptamine Concentration in Ritualistic Ayahuasca Users.
Ramaekers JG; Mallaroni P; Kloft L; Reckweg JT; Toennes SW; van Oorsouw K; Mason NL
J Cogn Neurosci; 2023 Sep; 35(9):1382-1393. PubMed ID: 37159257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
